Drug Patents owned by Rhythm

1. List of Imcivree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 25, 2027
New Chemical Entity Exclusivity (NCE) Nov 25, 2025
New Indication (I) Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in